Reach Us +1-947-333-4405
Human Immunodeficiency Virus Arrests Plasmacytoid Dendritic Cells in a Granzyme B<sup>high</sup> Tolerogenic State | OMICS International
ISSN: 2157-7560
Journal of Vaccines & Vaccination

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Human Immunodeficiency Virus Arrests Plasmacytoid Dendritic Cells in a Granzyme Bhigh Tolerogenic State

Bernd Jahrsdörfer1#, Verena Panitz2 and Dorit Fabricius2*#

1Laboratory of Cellular Immunology, Institute of Clinical Transfusion Medicine and Immunogenetics, Associate Professor of Clinical Pharmacology, Ulm University, Helmholtzstrasse 10, Ulm-8908, Germany

2Department of Pediatrics, Ulm University, Eythstrasse 24, Ulm-89075, Germany

3Authors are equally contributed

*Corresponding Author:
Dorit Fabricius
Assistant Professor of Pediatrics
Department of Pediatrics
Ulm University Eythstrasse
2489075 Ulm, Germany
Tel: +49 731 500 57376
Fax: +49 731 500 57042
E-mail: [email protected]

Received date: July 25, 2016; Accepted date: August 25, 2016; Published date: August 29, 2016

Citation: Jahrsdörfer B, Panitz V, Fabricius D (2016) Human Immunodeficiency Virus Arrests Plasmacytoid Dendritic Cells in a Granzyme Bhigh Tolerogenic State. J Vaccines Vaccin 7:337. doi: 10.4172/2157-7560.1000337

Copyright: © 2016 Jahrsdörfer B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Vaccines & Vaccination

Short Communication

The serine protease granzyme B (GzmB) is classically known to be an apoptogenic effector molecule produced by cytotoxic cells including NK cells and CD8+ T lymphocytes [1]. However, a series of further cell types are able to express GzmB, most of them in the absence of perforin. Below them are different antigen-presenting cells (APC) including B cells, monocyte-derived dendritic cells and plasmacytoid dendritic cells (pDC) [2-7]. Here, we report that GzmB contributes to a variety of dendritic cell-related functions including antigen uptake and T cell regulation, and that HIV can impact on these functions.

Recent years have uncovered a variety of non-cytotoxic roles of GzmB [8,9]. Of note, the cytotoxic function of T cells and NK cells results from GzmB being secreted in the presence of the pore-forming protein perforin (Pfn). This allows GzmB to reach the cytosol of target cells after exocytosis, where it may then activate apoptosis-inducing enzymes including caspases, DNAses and BID [1]. In contrast, certain immune cells including plasmacytoid dendritic cells (pDC) and B cells can produce GzmB only, but not Pfn [6,10-12]. GzmB secreted by these APC types therefore primarily encounters substrates with an extracellular or membrane-close localisation such as extracellular proteins or membrane-bound receptors [8]. As a result, these cells develop a strong immunoregulatory potential based on GzmBdependent cleavage of the T cell receptor (TCR)-ζ-chain [6,9-13]. Degradation of the TCR-ζ-chain by GzmB directly limits the proliferative capacity and survival of effector T cells.

GzmB produced by APC however may not only play an important role for their interaction with T cells, but also for antigen processing. Recently, GzmB was shown to enhance both the uptake of antigens by release of “eat-me” signals on dying cells as well as their crosspresentation [14,15]. Importantly, the cleavage of peptides by GzmB can result in fragments that represent neo-antigens, allowing the establishment of increased immune responses towards such antigens [16,17]. This suggests that antigens generated by GzmB are principally more immunogenic than antigens generated by other proteases. If GzmB-borne antigens arise, for example in the course of a T cellmediated attack of virus-infected cells, they may pose a substantial risk of triggering autoimmune responses. Therefore, GzmB produced by pDC and other APC is partly secreted into the extracellular space, where it can prevent early activation of unspecific T cells as described above (Figure 1, middle panel).


Figure 1: Current hypothesis for the maturation of plasmacytoid dendritic cells. Maturation of pDC precursors occurs in a biphasic process. During the first phase, pDC develop a tolerogenic phenotype in response to different cytokines including IL-3, IL-10 and IL-21. This phenotype involves the production of large amounts of the serine protease GzmB, which is involved not only in the suppression of effector T cell responses, but also in antigen uptake and proteasome-independent antigen processing. In the second phase, pDCs are rapidly (within 24 hours) matured in response to TLR ligands and CD40 ligand. GzmB is downmodulated, while costimulatory molecules and MHC/peptide complexes are simultaneously upregulated, resulting in a highly immunogenic and mature pDC phenotype. Our data suggest that the transition of pDC into this second phase is blocked during acute HIV infection, possibly by virus-associated factors antagonizing CD40- and TLRmediated signals.

Simultaneously, GzmB facilitates antigen uptake and processing into immunogenic fragments for cross-presentation. The GzmBhigh phase of pDC maturation is subsequently followed by a second phase, initiated by toll-like-receptor (TLR) ligand- and CD40 ligand-induced signals. These signals downregulate GzmB and induce co-stimulatory as well as antigen-presenting molecules on the pDC surface (Figure 1, right panel). Current data from our laboratory demonstrate that HIV enhances and maintains an immature and GzmBhigh phenotype in peripheral blood-derived pDC (Figure 2). This suggests that the transition of pDC into the second maturation phase is blocked by HIV, resulting in the persistence of a GzmBhigh tolerogenic state during HIV infection (Figure 1). Of note, while expression of GzmB is part of the maturity state of pDC, it is not believed to be causally involved in the transition of pDC from an immature into a mature state. Instead, virus-associated factors antagonizing CD40- or TLR-mediated signals may be responsible for the observed transition arrest [6,10]. Support for our hypothesis comes from an independent group, which demonstrated that gut-associated pDC from patients with HIV infection are also characterized by an immature phenotype and enhanced GzmB expression [18].


Figure 2: Human HIV increases GzmB secretion by pDC. PDC from five healthy donors were incubated for 16 hours in IL-3- supplemented (10 ng/ml) medium, in the presence or absence of IL-10 (25 mg/ml) and with or without (w/o) HIV 1 (5 ng/ml) as indicated. GzmB secretion was measured in supernatants by ELISA. Bar graphs represent average concentration values relative to medium control from five independent experiments. Error bars indicate standard error of means (SEM), p-values indicate statistically significant differences. Abbreviations: IL=Interleukin, HIV=human immunodeficiency virus, GzmB=granzyme.

Overall, our data suggest the maturation of pDC involves a dynamic process of GzmB expression and secretion, which is connected to different pDC functions and which is influenced by HIV. Further studies are necessary to elucidate, whether GzmB produced by pDC may serve as a target for therapeutic manipulation of immune responses after viral infections such as with HIV and during pDCbased vaccinations. For example, the suppression of pDC by pharmacological means, or direct neutralization of GzmB secreted by pDC may allow a better establishment of cellular antiviral immune responses during infection, resulting in faster clearance of virusinfected cells.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 8571
  • [From(publication date):
    October-2016 - Dec 10, 2018]
  • Breakdown by view type
  • HTML page views : 8486
  • PDF downloads : 85

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry


[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version